Reforming the public health system in England.


Journal

The Lancet. Public health
ISSN: 2468-2667
Titre abrégé: Lancet Public Health
Pays: England
ID NLM: 101699003

Informations de publication

Date de publication:
09 2022
Historique:
received: 28 06 2022
revised: 25 07 2022
accepted: 26 07 2022
entrez: 3 9 2022
pubmed: 4 9 2022
medline: 9 9 2022
Statut: ppublish

Résumé

The abolition of Public Health England (PHE) during the COVID-19 pandemic has raised concerns about the future of the public health system in the UK, particularly in England. The two new bodies established in haste to replace PHE prompt reflection on the executive agency's fate and the need to identify any lessons to ensure that a public health system is put in place that is fit for purpose. The UK COVID-19 Inquiry provides an opportunity to make recommendations, but it will need to act quickly to avoid recommendations being ignored. Two areas of concern are highlighted in this Viewpoint: the respective remits of the new bodies and their governance arrangements. Both issues demand urgent attention if the new structures are to succeed and avoid a similar fate to that which befell PHE. But underlying these concerns is a much larger challenge arising from the UK's broken political system. The political system in the UK suffers from several systemic weaknesses, including departmentalism, poor implementation, an inability or unwillingness of those in power to listen to the truth, and chronic short-termism at the expense of long-term planning. Overhauling the UK's dysfunctional political system is a prerequisite for successfully improving the public health system.

Identifiants

pubmed: 36057278
pii: S2468-2667(22)00199-2
doi: 10.1016/S2468-2667(22)00199-2
pmc: PMC9432864
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e797-e800

Informations de copyright

Copyright © 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of interests We declare no competing interests.

Références

BMJ. 2021 Sep 24;374:n2323
pubmed: 34561222
BMJ. 2020 Nov 20;371:m4476
pubmed: 33218977
BMJ. 2021 Apr 21;373:n996
pubmed: 33883162
Public Health. 2005 Oct;119(10):907-13
pubmed: 15979112
J Public Health (Oxf). 2020 Nov 23;42(4):778-783
pubmed: 31927582
BMJ. 2022 Jun 1;377:e070589
pubmed: 35649577
Lancet. 2020 Sep 26;396(10255):874
pubmed: 32979964
BMJ. 2021 Apr 1;373:n875
pubmed: 33795215

Auteurs

David J Hunter (DJ)

Population Health Sciences Institute and James Spence Institute, Newcastle University, Newcastle, UK. Electronic address: david.hunter2@newcastle.ac.uk.

Peter Littlejohns (P)

Centre for Implementation Science, Institute for Psychiatry, Psychology and Neuroscience, King's College London, London, UK.

Albert Weale (A)

Department of Political Science, University College London, London, UK.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH